Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for FDA
IP implications of the FDA guidance for use of AI in drug development IP implications of the FDA guidance for use of AI in drug development Reviewed by Dr Rose Hughes on Tuesday, June 17, 2025 Rating: 5
[Guest post] Covid-19 Treatments: The Issue of Orphan Drug Status and Patents [Guest post] Covid-19 Treatments: The Issue of Orphan Drug Status and Patents Reviewed by Frantzeska Papadopoulou on Friday, April 03, 2020 Rating: 5
When "mayo" is not mayonnaise, yet still is mayonnnaise: All a matter of the label? When "mayo" is not mayonnaise, yet still is mayonnnaise: All a matter of the label? Reviewed by Neil Wilkof on Sunday, August 20, 2017 Rating: 5
Allergan v Sandoz: when obvious is not obvious enough! Allergan v Sandoz: when obvious is not obvious enough! Reviewed by Stefano Barazza on Tuesday, May 07, 2013 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.